Edward Waldron

Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia

Karen Thudium Mueller, Shannon L. Maude, David L. Porter et al. · Blood · 2017 · 359 citations · Full text

Medicine, Oncology, Pharmacology +13

Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia

Karen Thudium Mueller, Edward Waldron, Stephan A. Grupp et al. · Clinical Cancer Research · 2018 · 222 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacology +17

Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL

Rakesh Awasthi, Lida Pacaud, Edward Waldron et al. · Blood Advances · 2020 · 143 citations · Full text

Life Sciences, Hematology, Oncology +17

A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function

Marije Slingerland, Dagmar Hess, Sally Clive et al. · Cancer Chemotherapy and Pharmacology · 2014 · 50 citations

Medicine, Pharmacokinetics, Pharmacology +10

A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function

Sunil Sharma, Petronella O. Witteveen, Martijn P. Lolkema et al. · Cancer Chemotherapy and Pharmacology · 2014 · 38 citations

Medicine, Pharmacokinetics, Pharmacology +10